Back to top
more

McKesson (MCK)

(Real Time Quote from BATS)

$607.08 USD

607.08
937,281

+57.77 (10.52%)

Updated Nov 7, 2024 11:10 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 22% (54 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Ecolab (ECL) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) third-quarter results are likely to reflect continued strength in its Global Industrial segment.

What's in the Cards for Illumina (ILMN) in Q3 Earnings?

by Zacks Equity Research

The extended lockdown issues in limited geographies, including Greater China, where Illumina (ILMN) has extensive business, are expected to have adversely impacted its top line during the third quarter.

Charles River (CRL) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Charles River's (CRL) CRADLE initiative for small and large biopharmaceutical clients is anticipated to have maintained its growth momentum.

Zacks.com featured highlights include Boise Cascade, RCI Hospitality Holdings, Iron Mountain, McKesson and National Fuel Gas

by Zacks Equity Research

Boise Cascade, RCI Hospitality Holdings, Iron Mountain, McKesson and National Fuel Gas are part of Zacks Screen of the week article.

Zimmer Biomet (ZBH) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet (ZBH) might have faced an upheaval in business, thanks to the global inflationary situation in terms of mounting labor and raw material costs.

What's in Store for West Pharmaceutical (WST) in Q3 Earnings?

by Zacks Equity Research

West Pharmaceutical's (WST) third-quarter results are likely to reflect strength in the Proprietary Products business. However, unfavorable currency movements are likely to hurt the top and bottom lines.

Stryker (SYK) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) third-quarter results are likely to reflect strong segmental performances.

Abiomed's (ABMD) Latest Impella Offering Approved by the FDA

by Zacks Equity Research

Abiomed's (ABMD) latest regulatory clearance for the Impella Low Profile Sheath is expected to improve patient outcomes.

DaVita (DVA) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

High labor costs, along with inflationary pressures, are likely to have weighed on DaVita's (DVA) third quarter's top line.

Here's How Investors Can Find Strong Medical Stocks with the Zacks ESP Screener

by Zacks Equity Research

Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

Non-COVID Diagnostics Sales to Aid Hologic (HOLX) Q4 Earnings

by Zacks Equity Research

Hologic's (HOLX) Molecular Diagnostics sales are likely to have been affected by the significant drop in demand for COVID-19 testing.

    Sweta Killa headshot

    5 Solid Dividend Growth Stocks for Q4

    by Sweta Killa

    Boise Cascade (BCC), RCI Hospitality (RICK), Iron Mountain (IRM), McKesson (MCK) and National Fuel Gas (NFG) seem compelling picks for Q4 amid volatility.

    Derek Lewis headshot

    Should Investors Consider These 3 Warren Buffett Purchases?

    by Derek Lewis

    Many people turn to the Oracle of Omaha when looking for stocks to add. After all, it's easy to understand why after seeing his track record.

    Is a Beat Likely for DexCom (DXCM) This Earnings Season?

    by Zacks Equity Research

    DexCom's (DXCM) third-quarter results are likely to reflect rising global awareness of its real-time CGM.

    Henry Schein (HSIC) to Report Q3 Earnings: What's in Store?

    by Zacks Equity Research

    We expect the Condor Dental buyout to have a beneficial impact on Henry Schein's (HSIC) results in the to-be-reported quarter.

    Baxter (BAX) to Report Q3 Earnings: Is a Beat in the Cards?

    by Zacks Equity Research

    Baxter's (BAX) third-quarter results are likely to reflect growth in its Medication Delivery and Advanced Surgery businesses. Hillrom's products are likely to have boosted sales.

    Hologic (HOLX) to Report Q4 Earnings: What's in the Cards?

    by Zacks Equity Research

    Hologic's (HOLX) interventional business is likely to have faced continued supply chain headwinds related to disposable biopsy needles, hampering its performance.

    Quest Diagnostics (DGX) Beats on Q3 Earnings, Ups Revenue View

    by Zacks Equity Research

    Banking on consistent improvement in the company's Base business, Quest Diagnostics (DGX) raised its full-year 2022 revenue guidance.

    Veeva Systems' (VEEV) New Launch to Streamline Clinical Data

    by Zacks Equity Research

    Veeva Systems' (VEEV) new offering is expected to speed up the aggregation and cleaning of clinical trial data, thereby making it usable.

    Abbott's (ABT) Q3 Earnings Top Estimates, 2022 EPS View Up (Revised)

    by Zacks Equity Research

    Abbott's (ABT) Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

    IDEXX (IDXX) to Report Q3 Earnings: What's in the Cards?

    by Zacks Equity Research

    IDEXX's (IDXX) CAG premium instrument placements are expected to have recorded significant growth in Q3 on the continued rise in Catalyst and premium hematology placements.

    STERIS (STE) to Report Q2 Earnings: What's in the Cards?

    by Zacks Equity Research

    STERIS' (STE) Dental arm revenues are expected to have been impacted somewhat by supply chain challenges.

    Abbott's (ABT) Q2 Earnings Top Estimates, 2022 EPS View Up

    by Zacks Equity Research

    Abbott's (ABT) Diabetes Care business continues to benefit from the growing sales of its flagship, sensor-based continuous glucose monitoring system, FreeStyle Libre.

    Intuitive Surgical (ISRG) Q3 Earnings Beat, Procedures Recover

    by Zacks Equity Research

    Intuitive Surgical's (ISRG) third-quarter results reflect health demand for procedures, partially offset by lower system sales and unfavorable currency.

    Veeva Systems' (VEEV) New Launch to Enhance Digital Trials

    by Zacks Equity Research

    Veeva Systems' (VEEV) new offering is expected to meet the requirements of patients, sites and sponsors, thereby streamlining trial activities.